Koers InMed Pharmaceuticals Inc Deutsche Boerse AG
Aandelen
CA13764X1069
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- EUR | - |
Omzet 2024 * | 7,3 mln. 5,36 mln. 4,93 mln. | Omzet 2025 * | 9,12 mln. 6,7 mln. 6,16 mln. | Marktkapitalisatie | 2,43 mln. 1,79 mln. 1,64 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 0,33 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,27 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,16% |
Recentste transcriptie over InMed Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Chief Operating Officer | - | 05-11-18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11-02-22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Andrew Hull
CHM | Chairman | 61 | 12-09-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,87 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |